Immunity Generated from Covid-19 Vaccines Differs from an Infection
Intramuscular vaccinations are the <i>most important first step </i>and will keep hospitalization down. But intramuscular vaccination for respiratory viruses does not provide long lasting immunity to the surface mucosa tissues of the upper respiratory tract. The IgG antibodies in body serum do seep into the lower lungs and provide robust protection from serious disease, but they do not prevent infections very long in the nose, sinuses, or throat. This is the disparity many studies are now highlighting but failing to acknowledge the cause of.<p>The required next step is intranasal vaccination to recruit B and T cells to the upper respiratory mucosa and have the B cells produce local IgA antibodies. This would actually stop infections (infections defined from nasal swab testing).<p>It is up to the NIH and other large organizations in the world to get this messaging out there. There are two types  of &quot;breakthrough&quot;. There&#x27;s the fact that intramuscular vaccinations don&#x27;t protect the upper respiratory mucosa, and then there&#x27;s the very rare cases when sars-cov-2 actually manages to infect body organs and the lower lungs. They are entirely different things.<p>The variants currently circulating don&#x27;t play a huge role in this discrepancy. We&#x27;d be seeing the same amount of upper respiratory mucosa infections (not hospitalizations) even if there were no delta and it was just alpha&#x2F;beta&#x2F;gamma or even original wuhan sequence sars-cov-2.<p>ref: <a href="https:&#x2F;&#x2F;www.gov.uk&#x2F;government&#x2F;publications&#x2F;long-term-evolution-of-sars-cov-2-26-july-2021" rel="nofollow">https:&#x2F;&#x2F;www.gov.uk&#x2F;government&#x2F;publications&#x2F;long-term-evoluti...</a> page 5, #8. &quot;Whilst we feel that current vaccines are excellent for reducing the risk of hospital admission and disease, we propose that research be focused on vaccines that also induce high and durable levels of mucosal immunity in order to reduce infection of and transmission from vaccinated individuals. This could also reduce the possibility of variant selection in vaccinated individuals.&quot;<p>ref: <a href="https:&#x2F;&#x2F;science.sciencemag.org&#x2F;content&#x2F;373&#x2F;6553&#x2F;397" rel="nofollow">https:&#x2F;&#x2F;science.sciencemag.org&#x2F;content&#x2F;373&#x2F;6553&#x2F;397</a>  &quot;the ideal vaccination strategy may use an intramuscular vaccine to elicit a long-lived systemic IgG response and a broad repertoire of central memory B and T cells, followed by an intranasal booster that recruits memory B and T cells to the nasal passages and further guides their differentiation toward mucosal protection, including IgA secretion and tissue-resident memory cells in the respiratory tract.&quot;<p>ref: <a href="https:&#x2F;&#x2F;www.nature.com&#x2F;articles&#x2F;s41577-021-00550-x" rel="nofollow">https:&#x2F;&#x2F;www.nature.com&#x2F;articles&#x2F;s41577-021-00550-x</a>